A Phase 1 Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GS-5745 in Subjects With Chronic Obstructive Pulmonary Disease

Trial Profile

A Phase 1 Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GS-5745 in Subjects With Chronic Obstructive Pulmonary Disease

Completed
Phase of Trial: Phase I

Latest Information Update: 13 Feb 2015

At a glance

  • Drugs Andecaliximab (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Adverse reactions
  • Sponsors Gilead Sciences
  • Most Recent Events

    • 09 Feb 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 14 Sep 2014 Planned End Date changed from 1 Nov 2014 to 1 Oct 2014 as reported by ClinicalTrials.gov record.
    • 14 Sep 2014 Planned primary completion date changed from 1 Nov 2014 to 1 Oct 2014 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top